1 Min Read
April 5 (Reuters) - On Target Laboratories:
* FIRST PATIENT TREATED IN PIVOTAL PHASE 3 TRIAL TO EVALUATE OTL38 IN THE DETECTION OF OVARIAN CANCER Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.